A Strategy for Alcobra’s Do or Die Phase 3 Results
Research - A risk-mitigating strategy for being involved in Alcobra’s (ADHD) upcoming phase 3 results in ADHD.
Premium: Read NowResearch
InterMune Bought by Swiss Powerhouse Roche
Research - Roche (RHHBY) is purchasing InterMune (ITMN) for $8.3B, or $74 per share in cash. Admittedly, this caught me off guard. The world’s leading provider of cancer care products is better known … Continue Reading
Read Now
Buyers are Supposedly Circling InterMune: Here’s Our Take
Research - InterMune’s (ITMN) stock rose 14 percent last Wednesday, closing at a 14-year high of $52.06, on rumors that big pharma is lining up to bid for … Continue Reading
Read Now
Success for Amicus, +50% for PropThink Members
Research - Success for Amicus Therapeutics (FOLD) in a study of migalastat meant +50% for PropThink subscribers who followed our trade recommendation.
Read Now
Pharmacyclics’ Quarterly Results Support Long-Term Imbruvica Thesis
Research - OWN PCYC as Imbruvica continues to secure foothold in oncology. Cash and emerging pipeline offer options diversification for this small company. Second quarter results demonstrate continued growth … Continue Reading
Premium: Read Now
Takeaways from OncoGeneX’s Second Quarter Results
Research - Takeaways from OncoGeneX's (OGXI). Knowing this could make or save you some $$.
Premium: Read Now
MannKind Lands a Partner, Bull/Bear Debate Continues
Research - Drug developer (and battleground biotechnology stock) Mannkind Corp (MNKD) has partnered with Sanofi (SNY) for the global commercialization of its approved inhaled insulin product, Afrezza. MNKD jumped 20% on … Continue Reading
Read Now